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To improve patients’ quality of life and decrease pollution risks to medical personnel, we tested the usefulness of a
nitric oxide (NO) inhalation system consisting of a nasal cannula and a demand valve in an open circuit system. To
estimate the content of NO entering the lung with the open system, concentrations of NO and nitrogen dioxide
(NO2) were measured in a mechanical lung model, and then nitrocylhaemoglobin (NO-Hb), methaemoglobin (Met-
Hb), and nitrite (NO27) + nitrate (NO37) concentrations in venous blood were measured in eight healthy subjects.
Exhaust NO and NO2 in the open system were also observed in 14 healthy subjects. In the lung model, NO
concentration delivered with the open system was approximately 1/11 of that in the gas tank. Increases in Met-Hb
and NO27 +NO37 with the open system showed that the concentration of delivered NO was approximately 1/9 of
that in the gas tank. The open system reduced exhaust NO to 1/10 in human subjects. These data suggest that this
NO inhalation system delivers sucient NO to spontaneously breathing patients. In addition, these findings
indicate that there is little environmental toxicity associated with the open circuit system.
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Inhaled nitric oxide (NO) causes selective pulmonary
vasodilatation in pulmonary hypertension with acute
respiratory distress syndrome (ARDS) (1,2), primary
pulmonary hypertension (PPH) (3,4), persistent pulmonary
hypertension of the new born (5,6), chronic obstructive
pulmonary disease (COPD) (7), lung fibrosis (8) and
congenital heart disease (9). A long-term administration
of NO to spontaneously breathing patients has many
problems awaiting solution, such as restriction of activities
and air pollution by exhaust NO and nitrogen dioxide
(NO2). Recently, Channick and associates reported on an
open circuit NO inhalation system with a demand valve via
nasal cannula to ambulatory patients with pulmonary
hypertension (10). The open circuit system for pulsed
delivery of NO via nasal cannula is feasible for long-term
NO inhalation and leads to significant improvement in
pulmonary hypertension. Katayama et al. have reportedRecevied 14 October 1998 and accepted in revised form 2
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pulmonary artery pressure and pulmonary vascular resis-
tance (PVR) as eectively as continuous NO inhalation in
pig lungs and in patients with pulmonary hypertension (11).
Although these systems are useful to decrease exhaust NO
and NO2, previous reports have not described the detailed
functioning of the open system. The purpose of this study
was to evaluate the eect of the open circuit system on the
decrease in exhaust NO and NO2 in human subjects.
Materials and methods
The study was approved by the Medical Ethics Committee
of the University of Tsukuba and informed consent was
obtained from each participant after a thorough explana-
tion of the purpose of the study.
EXPERIMENT A: A MECHANICAL LUNG
MODEL
To predict concentrations of NO and NO2, a mechanical
lung model was used (Fig.1). The model consisted of two
anti-static latex bags inside a 15-l cylindrical plastic airtight
container, which allowed free movement of the bags. The
bottom of the container was made of soft rubber, which# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. The mechanical lung model. The bag-in the-
container design represents the lung, thorax and
diaphragm. The Piston ventilator provides negative
pressure inside the container. The bags are then passively
extended for the inspiration period in the mechanical lung
model.
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piston ventilator that generated negative pressure. Exhaled
tidal volume (TVE), respiratory rate (RR), minute ventila-
tion (V’E) and inspired oxygen concentration (FiO2), were
measured on a breath-by-breath basis by an Aeromonitor
TM AE-280 (Minato Medical Science Co., Tokyo, Japan),
consisting of a hot-wire flow meter and oxygen and carbon
dioxide gas analysers. A non-rebreathing valve was
mounted on the lung model, and NO and/or 100% oxygen
(O2) via a nasal cannula, together with room air, were
administered from the inspired side via an anatomical nose
model with two 5-mm diameter holes. A nasal cannula
indicating NO gas and another nasal cannula indicating O2
were connected to the anatomical nose model. The nasal
cannula and anatomical nose are loosely connected
allowing room air to circulate freely between them. Expired
gas was collected in a 10-l tedlar bag. Concentrations of NO
and NO2 in the bag were then immediately measured both
with and without the demand valve at a 05 or a 1 lmin71
flow rate, respectively. We observed the mechanical lung
model at 10 to 30min71 of RR with 500 ml of TVE and at
200 to 500 ml of TVE with 15min71 of RR. Before the
experiment, we measured the concentrations of NO and
NO2 taken from the latex bag, and the expired circuit.
Because these concentrations were equal, we considered the
concentration of NO and NO2 taken from expired circuit to
be equal to those in the latex bag. We measured the
concentration of NO in the cylindrical plastic container
during a 10 min 368 ppm NO inhalation. The concentra-
tion of NO was under 1 ppm, demonstrating that the
leakage of NO from the latex bag could be ignored in this
model. Concentrations of NO and NO2 were measured on a
chemiluminescence analyser CLM-500 (Simazu Co., Tokyo
Japan). Concentrations of inspired NO nitrogen (N2)
balance were 0, 44, 93, 186 and 368 ppm in the tank.EXPERIMENT B: MEASUREMENTS OF
NO-HB, MET-HB, AND NO27 + NO37
To predict NO concentration in the human lung with the
open system, eight healthy non-smoking volunteers (five
men and three women) with a mean age of 309 years (range
23–40) inhaled NO for 90 min. They inhaled NO using
three dierent methods as follows: (i) 40 ppm NO via an
airtight mask, (ii) 80 ppm NO via an airtight mask, and
(iii) 368 ppm NO in the gas tank via a nasal cannula with
the demand valve set equivalent to 1 l min71 of continuous
flow. There was an interval of at least a 1 week between
each experiment. Blood and plasma samples for NO-Hb,
Met-Hb, and NO27 +NO37 were obtained before the start
of each NO inhalation, and at 30, 60 and 90 min during NO
inhalation. Systemic blood pressure (BP), percutaneous
oxygen saturation (SpO2), pulse rate (PR), RR, TVE, V’E,
and electrocardiogram were monitored throughout the
experiments. For the airtight mask, NO gas was made by
mixing 4000 ppm NO with N2 and room air in a 10-l tedlar
bag just prior to directly connecting a non-rebreathing
valve to a detector and the airtight mask. The flow of gas
was controlled by a mass flow controller (SEC Co. Ltd.,
Tokyo, Japan) and adjusted by measuring the concentra-
tion of NO in the inspired gas with a chemiluminescence
analyser.
Blood samples were taken into 3-mm ID quartz capillary
tubes and were deep-frozen in liquid nitrogen before NO-
Hb analysis. NO-Hb levels were analysed by electron
paramagnetic resonance (ERS) spectrometry as previous
described (12). ESR spectra were recorded using an X-band
spectrometer (JoeL model RE 3X) at 71508C. The ESR
spectrometer settings were as follows: incident microwave
power, 8 mW; modulation frequency, 100 kHz; modulation
amplitude, 032 mT; microwave frequency, 91 GHz. The
double-integrated area of NO-Hb agreed with that of
CuSO4-EDTA (13). Thus CuSO4-EDTA (1 mM) was used
as a standard. Blood samples were also taken into tubes
containing 125 U of heparin, and Met-Hb levels were
measured by light absorption using a co-oximeter (OSM3,
Radiometer, Copenhagen, Denmark). NO27+NO37 in
plasma samples were analysed using a high-performance
liquid chromatography technique based on the Griess
reaction, as previously described (13).
EXPERIMENT C: EXHAUST
CONCENTRATIONS OF NO AND NO2
Fourteen healthy non-smoking volunteers (10 men and four
women) with a mean age of 313 years (range 23–40)
inhaled NO at 0, 44, 93, 186, and 368 ppm in a gas tank via
a nasal cannula with a demand valve. The demand valve
was set to generate a pulsed flow, which was equivalent to
05 to 2 lmin71 of the continuous flow. Subjects then
inhaled NO in the same manner without a demand valve;
these latter administrations of NO were at a continuous
flow rate 05 to 2 lmin71. The mouth and nose as well as
the nasal cannula were covered with an airtight mask that
was connected to a detector and a non-rebreathing valve.
FIG. 2. Concentration- and flow-response curves of NO in
the lung model during NO inhalation via a nasal cannula
with (*) or without (*) the demand valve: (a) the flow
rate is 05 lmin71; (b) the flow rate is 1 lmin71; (c)
inhaled NO concentration is 93 ppm in the gas tank. The
tidal volume is 500 ml and respiratory rate is 20min71.
Data are expressed as meanSD (n=5). (*)shows
significant dierences between measurements with and
without the demand valve (P5005).
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was collected in a 10-l tedlar bag, and the concentrations of
NO and NO2 were measured immediately. Exhaust NO and
NO2 were measured 15 min after each change of NO gas
tanks and flow rates. To determine the interval time, we
preliminary confirmed that concentrations of exhaust NO
and NO2 were stable for 10 to 90 min in this system.
STATISTICS
Data are expressed as meanSD. Statistical comparisons
were performed by two-way analysis of variance (ANO-
VA). If a significant variance was detected, individual
group dierences were determined using Dunnett’s test. A
P-value of less than 005 was considered statistically
significant.
MATERIALS
Sodium nitrite, sodium nitrate, and EDTA were purchased
from Sigma (MO, U.S.A.). The NO gas in the N2 balance,
pure N2 gas, and pure O2 gas were purchased from
Sumitomo Seika Chemicals Co., Ltd., Osaka Japan. The
NO2 concentration of each NO gas tank was below 005%
of the NO concentration.
A demand valve device, which was modified from an
inspiration-phase oxygen delivery device for home oxygen
therapy, was a gift from Teijin Ltd. (Tokyo, Japan). This
device detects pressure changes in excess of 006 cm H2O for
001 sec. The demand valve senses the change from
expiration to inspiration, and opens a valve to provide
NO for the initial phase of the inspiration period. The
opening time is determined by an internal microcomputer,
which calculates the mean of the previous two inspiration
periods. The opening time is approximately 30% of the
inspiration period. In the continuous flow system, the gas
flow during the expiration period was not inspired, and the
gas flow during the later phase of the inspiration period
might have stopped at the dead space and had not reached
the alveoli. The demand valve is able to reduce the amount
of supplied gas to a third of that used in the continuous
flow system; it cut o the gas flow during the expiration
period as well as during the later phase of the inspiration
period. Under the above computerized settings, the demand
valve generates gas flow in pulses, which is equivalent to
continuous flow as regards reaching the alveolar space.
Although the flow rate with the demand valve was set to be
equivalent to that of continuous flow, the outflow from the
tank was in fact a third that of continuous flow.
Results
EXPERIMENT A: A MECHANICAL LUNG
MODEL
To estimate the eect of the demand valve, we compared
the NO concentration in the mechanical lung model both
with a demand valve and without a demand valve (constantflow system). In both systems, the NO concentration
increased in proportion to increases in NO concentration
in the tank and flow rate (Fig. 2). In the case of the
05 lmin71 flow rate, the NO concentration with a demand
valve was slightly less than that without a demand valve
[Fig. 2(a)]. In the case of the 05 lmin71 flow rate with a
demand valve, the NO concentration in the lung model was
approximately 1/40 of that in the gas tank. There was no
dierence in NO concentration between inhalation with or
without a demand valve and at the 1 lmin71 flow rate
[Fig. 2(b)]. In the case of the 1 lmin71 flow rate, the NO
concentration in the lung model was approximately 1/11 of
that in the gas tank. In the case of the 2 lmin71 flow rate,
there was greater NO concentration with than without a
demand valve [Fig. 2(c)]. The NO concentration varied
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concentration was under 005 ppm throughout all experi-
ments.
To evaluate the eect of the increase in FiO2 on
concentrations of NO and NO2, O2 (1–5 lmin
71) was
inhaled with NO (93 ppm in the gas tank) via a nasal
cannula with a demand valve. There were no changes in the
concentration of NO and NO2, regardless of increases in
FiO2 (data not shown).
EXPERIMENT B: MEASUREMENTS OF NO-
HB, MET-HB, AND NO27 + NO37
When NO was administered to subjects via an airtight mask
for 90 min, Met-Hb and NO27+NO37 concentrations
increased in a time- and a dose-dependent manner (Fig. 4).
Met-Hb and NO27+NO37 concentrations in response to
40 ppm NO administered via an airtight mask were similar
to those in response to 368 ppm NO in the gas tankFIG. 3. Eects of changes of tidal volume (TVE) and
respiratory rate (RR) on expired NO during NO
inhalation via a nasal cannula with (*) or without (*)
the demand valve in the lung model. The concentration of
inspired NO is 93 ppm in the gas tank and the flow rate is
05 lmin71: (a) the eect of changes of TVE with 15/min
of RR; (b) The eect of changes of RR with 500 ml of
TVE.
FIG. 4. Time-relation curves of (a) Met-Hb and (b) nitrite
and nitrate in response to NO inhalation for 90 min by
healthy subjects. The concentrations during 368 ppm in
the gas tank of NO inhalation via a nasal cannula with the
demand valve with setting, which is equivalent to a
1 l.min71 flow rate of constant flow (*), during 40 ppm
in the closed circuit of NO inhalation via an airtight mask
(~), and during 80 ppm in the closed circuit of NO
inhalation via an airtight mask (&) are shown. Data are
expressed as meanSD (n=8). (*)shows significant
dierences between 80 ppm NO and others (P5005).administered via a nasal cannula with the demand valve at a
flow rate of 1 lmin71. The NO-Hb signal was not detected
by ESR spectrometry in any of the blood samples, although
a CuSO4–EDTA signal was detectable. BP, PR, RR, and
the electrocardiogram were unchanged during the experi-
ments. Adverse eects of NO were not seen, expect for one
complaint of mild nasal congestion in a subject using a
nasal cannula. Observation with a rhinoscope showed
normal nasal mucosa after the experiment.
EXPERIMENT C: EXHAUST
CONCENTRATIONS OF NO AND NO2
Without a demand valve at a flow rate of 0.5 lmin71,
the exhaust NO concentration increased in proportion to
546 T. SAITO ET AL.the inhaled NO concentration in the gas tank. However, the
exhaust NO concentrations did not increase in the same
manner when the demand valve was set equivalent to
05 lmin71 of the continuous flow [Fig. 5(a)]. To determine
the ecacy of NO reduction with the demand valve, the on/
o ratio of the demand valve (exhaust NO concentration
with the demand valve/exhaust NO concentration without
the demand valve) was calculated. The ecacy of reduction
achieved by the demand valve was approximately 1/10;
similar results were obtained regardless of the change in
inhaled NO concentration in the gas tank [Fig. 5(b)]. BP,
PR, and RR did not change, and the subjects did not
complain of discomfort.
The concentration of exhaust NO also increased in
proportion to the flow rate of NO inhaled without a
demand valve. However, the exhaust NO concentrations
were not similarly increased with a demand valve [Fig.
6(a)]. The ecacy of reduction with the demand valve was
decreased in comparison with the increase in the flow rate
[Fig. 6(b)]. The exhaust NO2 concentration with the
demand valve was less than 01 ppm throughout each of theFIG. 5. (a) Exhaust NO concentrations in response to
inhaled NO concentration in the gas tank with (*) or
without (*) the demand valve (the flow rate is
05 lmin71). (*)shows significant dierences between
measurements with and without the demand valve
(P5005). (b) On/o ratios of the demand valve are
shown (on/o ratio is calculated by the formula shown in
the text). Data are expressed as meanSD (n=14).
FIG. 6. (a) Exhaust NO concentrations in response to flow
rate setting with (*) or without (*) the demand valve
(inhaled NO concentration is 93 ppm in the gas tank).
(*)shows significant dierences between measurements
with and without the demand valve (P5005). (b) On/o
ratios of the demand valve are shown (on/o ratio is
calculated by the formula shown in the text). Data are
expressed as meanSD (n=14).experiments. Increases in concentrations of exhaust NO
and NO2 were calculated over a 1-h period in a standard
room (3111m3) at Tsukuba University Hospital. Concen-
trations of exhaust NO and NO2 were under 3 ppb and 01
ppb, respectively, when 44 ppm of NO in the tank was
inhaled for 1 h via a nasal cannula with the demand valve
setting at equivalent to 05 lmin71 of the continuous flow.
Discussion
Recently, several investigators have reported that the initial
phase of NO inhalation during the inspiration period is
eective in reducing pulmonary artery pressure. Katayama
et al. demonstrated ‘spiked’ 100 ppm NO during early
inspiration and found this to be as eective as administer-
ing 40 ppm of continuous NO to pig and patients with
pulmonary hypertension (11). Channick et al. have shown a
significant decrease in pulmonary artery pressure and PVR
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patients with pulmonary hypertension (10). In this study,
we used a similar system and demonstrated that little NO
and NO2 exhaust is produced in an open NO inhalation
system employing a nasal cannula with a demand valve that
supplied NO to spontaneously breathing subjects. Concen-
trations of NO and NO2 in the mechanical lung model and
measurements of Met-Hb and NO27+NO37 in healthy
subjects both suggest that a sucient amount of NO is
supplied with this system.
To prevent injury to medical personnel involved in
patient care, concentrations of exhaust NO-related pro-
ducts, especially NO2, must be decreased to the lowest
possible levels. Although the Occupational Safety and
Health Administration has set the 8 h maximal working-
exposure level at 3 ppm of NO2 (14), recent studies have
demonstrated that 15 ppm NO2 may cause injury to the
lungs over time (15,16). In our NO inhalation system,
exhaust NO and NO2 concentrations remained low while
the demand valve was in use; this was true at all flow rates
and source tank concentrations. With 44 ppm NO at a flow
rate of 05 lmin71, exhaust NO and NO2 were 013 ppm
and 006 ppm, respectively, and NO and NO2 per hour in a
standard room at Tsukuba University Hospital were
calculated as under 3 ppb and 01 ppb, respectively. These
measurements are lower than the environmental standard
for NO2 in Japan (006 ppm). Since the rate of conversion
to NO2 from NO is increased in the presence of O2 (17), we
examined the eects of an increase in FiO2 on the
production of NO2. An increase in NO2 was not observed
in the mechanical lung model within the FiO2 range of 020
to 032; these findings suggest that inhalation of NO and O2
together is safe within this FiO2 range.
There are two reasons for decreased NO and NO2
exhaust with the use of the demand valve. First, the demand
valve system is designed to reduce the supplied gas volume
to 1/3 of that used in a constant flow system; this is because
the gas is inhaled only during the inspiration period.
Second, as inhaled NO gas reaches the alveolar space, it is
inactivated by rapid absorption and combination with
haemoglobin. Since the demand valve supplies NO in the
initial phase of the inspiration period, subsequent inspired
air pushes NO already in the airway into the alveolar space.
It is dicult to measure the concentration of NO in the
human lung directly. Several studies have demonstrated
that the levels of blood Met-Hb and NO27+NO37 increase
according to inhaled NO (18,19,20). Therefore, we mea-
sured these products in the blood. Our results indicated that
NO at 368 ppm in the gas tank with 1 lmin71 of flow rate,
inhaled via a nasal cannula, supplied the same concentra-
tion of NO to the body that was supplied by an airtight
mask via closed circuit NO at 40 ppm. This conversion rate
(9:1) was similar to the data obtained in the mechanical
lung model (11:1). It is important to predict concentrations
of delivered NO, because the correct inhaled concentration
could not be measured with this system and the haemody-
namic changes in response to NO inhalation are dierent in
each patient.
We could not detect NO-Hb in the blood in this study.
Although NO-Hb has been detected in rats and mice(12,21), it has not been detected in pigs, piglets and dogs
(18,19,22). In vitro formation of NO-Hb occurs only with
deoxyhaemoglobin in the complete absence of O2 and not
with oxyhaemoglobin (23). NO-Hb itself converts to Met-
Hb in the presence of O2, limiting NO-Hb accumulation
(24). Production of NO-Hb may therefore be extremely
limited, when most haemoglobin is saturated in healthy
subjects.
In this system, inhaled NO concentrations vary according
to TVE and RR. To decrease the influence of this problem,
a minimal dose, e.g., less than 40 ppm in the gas tank,
should be delivered via this system. When the NO level is 40
ppm in the gas tank and is flowing at a 05 lmin71 via a
nasal cannula (corresponding to 1 ppm in the closed circuit
NO system delivered via an airtight mask), the variation of
NO concentration in the human lung might be within 1–3
ppm. Recent data suggest that under 15 ppm of NO is
eective for achieving an improvement in pulmonary
circulation and gas exchange in patients with ARDS
(25,26). This system is not only simple, easy, and safe; it
also can supply such low concentrations of NO.
A large study of NO inhalation in ARDS suggested that
30 days NO inhalation does not alter mortality although it
does reduce the frequency of severe respiratory failure (27).
The eect of long-term NO inhalation in patients with
respiratory failure, in addition to ARDS, must be examined
further. This system may be useful for the long-term supply
of NO in these patients. Katayama et al. reported that NO
inhalation worsens gas exchange in patients with COPD
(28). In COPD patients, it is necessary to inhale NO and
oxygen simultaneously. The open NO inhalation system
employing a nasal cannula can be easily added to a home
oxygen therapy system.
In summary, an open NO inhalation system consisting of
a nasal cannula and a demand valve significantly decreased
the exhaust NO and NO2 in spontaneously breathing
healthy subjects. This system may be useful for improving
the pathophysiological condition of ambulatory patients
with pulmonary hypertension.
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